Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2012 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BIOMARIN PHARMACEUTICAL INC | 8 | Q2 2017 | 7.8% |
EDWARDS LIFESCIENCES CORP | 8 | Q2 2017 | 8.4% |
VERTEX PHARMACEUTICALS INC | 8 | Q2 2017 | 7.1% |
SHIRE PLC | 7 | Q4 2016 | 6.4% |
QIAGEN NV | 7 | Q1 2017 | 7.4% |
BIOGEN INC | 6 | Q1 2017 | 7.0% |
COOPER COS INC | 6 | Q1 2016 | 9.1% |
INCYTE CORP | 6 | Q2 2017 | 6.6% |
NEUROCRINE BIOSCIENCES INC | 5 | Q2 2017 | 9.1% |
IRONWOOD PHARMACEUTICALS INC | 5 | Q2 2017 | 7.1% |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2017-08-11 |
13F-HR | 2017-05-12 |
13F-HR | 2017-02-13 |
13F-HR | 2016-11-10 |
13F-HR | 2016-08-12 |
13F-HR | 2016-05-13 |
13F-HR | 2016-02-12 |
13F-HR | 2015-11-13 |
13F-HR | 2015-08-13 |
13F-HR | 2015-05-13 |
View BLUE JAY CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.